Monday, August 6, 2012

>CITY UNION BANK


Healthy business growth, robust fees, stable asset quality; Buy 

City Union Bank’s 1QFY13 profits were driven by modest net interest income, healthy fees and lower provisions. We retain a Buy as prudent loan growth, stable productivity and robust asset quality are likely to drive profitability and sustain an RoA of 1.7% over FY12-14. The high tier-1 capital and low proportion of stressed assets provide considerable
balance -sheet comfort.


Healthy business growth, strong savings-deposit growth. Advances grew 33.2% yoy, faster than deposits at 25.2% yoy, increasing credit deposit by 447bps yoy to 74.9%. NIM fell 41bps yoy to 3.2%, led by a larger share of priority-sector loan disbursements (where yields are lower) and a 101-bp yoy fall in share of CASA to 17.5%. While current deposits grew slower (8.8% yoy), a sector-wide trend in 1QFY13, savings deposits grew a robust 25.6% yoy and comprise 61% of CASA (57% in 1QFY12).


Robust fee-income, investments in branches continue. Fee income grew 26.1% yoy and improved 8bps yoy to 1.42% of assets. Cost-to assets rose 26bps yoy to 2% as the number of branches rose 10% yoy to 303. Investment in distribution is likely to persist, albeit in low-cost semi urban/ rural areas, since the bank has 79 branch licenses and aims to reach 500 branches by FY15. We expect the bank’s branches to see better operating leverage with cost-to-assets estimated at 1.7% over FY13-14.


High proportion of secured loans, capital-raising plans. With fresh slippage of `450m (1.4% of loans), gross NPA rose 11% qoq. NPA coverage (excl. technical write-offs) fell 463bps qoq to 53.6%. Yet a high proportion of secured loans (97%) and a strong track record of asset quality are reassuring. Likely capital-raising in FY13 via a `2.5bn rights issue would improve the bank’s capital adequacy (tier-1 of 11.3%).


Valuation. At our Sep’13 target, the stock would trade at 1.9x FY13e and 1.5x FY14e ABV. Our target is based on the two-stage DDM (CoE: 15.6%; beta: 0.8; Rf: 8%). Risk: higher-than-estimated increase in NPA.




RISH TRADER

Saturday, August 4, 2012

>PERSISTENT SYSTEMS LIMITED


Persistent Systems Ltd. (PSL) reported its Q1FY13 results which were inline on the revenue front but disappointed at the operating level. The revenue in $ terms grew 1.3% sequentially and 9.8% Y-o-Y to $54.9 mn due to higher IP-led revenues (grew 16.4% sequentially and 150.2% Y-o-Y to $7.6 mn) however linear business remained muted.


EBITDA margin contracted by 166 bps sequentially to 26.8% compared to expectations of significant expansion on the back of rupee depreciation. This was primarily due to unexpected wage hike of 4.2% for onsite employees, product acquisition (leading to hiring of 72 people in Malaysia and 12 in US) and higher SG&A expenses. Offshore salary hike of 10% is due in Q2FY13 hence margins will be under pressure going forward.


Net profit stood at Rs 416 mn up 50.8% Y-o-Y and only 0.9% sequentially despite strong rupee depreciation of 9.7% in the quarter due to EBITDA margin contraction and forex loss of Rs 92mn.


Linear business performance modest but PSL's IP focus bearing fruit
IP revenues contributed to 13.9% of the total revenue as against 12.1% in Q4FY12 while it more than doubled Y-o-Y to $7.65mn. The network performance management product acquired from IBM contributed to ~$0.75mn while the full-quarter contribution from Openwave of ~US$0.6mn also added to the incremental revenue sequentially. The linear business on the other hand continued to remain subdued as revenue declined 0.8% sequentially (0.6% Q-o-Q decline in volumes).


Revenues from four focus areas grew faster at 5.3% sequentially
The four focus areas of cloud, collaboration, mobility, and BI contributed ~39% to the overall revenues in Q1FY13 and grew 5.3% sequentially.


Wage hikes & headcounts
The company has given a wage hike of 4.4% to its onsite employees and a hike of 9.9% is in the offing to its offshore employees in the Q2FY13. Headcount declined for the 3rd quarter in a row with attrition increasing by ~60 bps sequentially to 18.9%. PSL absorbed the full employee cost (72 employees in Malaysia and 12 in the US) related to the end-of-life product acquisition from IBM (present for 2/3rds of the quarter) whereas revenue contribution from the same was modest in the quarter.


The large Forex loss in Q1FY13 could reverse in H2FY13
PSL reported forex losses of ~Rs121mn comprising of Rs91mn loss on the hedges and Rs30mn loss on asset translation. However, given that the hedges in Q3-Q4FY13 are at favorable rates, i.e. upwards of Rs57/$, we expect forex gains on hedges in H2FY13 if the exchange rate remains at similar levels.


Management guidance
Management has guided that the company would surpass Nasscom's industry growth forecast of 11-14% Y-o-Y (USD revenue) for FY13 with incremental growth driven by growth from the key focus areas of cloud, analytics and collaboration from partnerships with companies such as SalesForce.com, IBM, Cisco etc. It expects to maintain or improve EBIDTA margins. Though the IP revenues are expected to remain volatile going forward, the company expects good growth from it.



Outlook
Revenue momentum should pick up in the next few quarters (from revenue contribution from the
product acquisitions). We would expect margins to remain under pressure in Q2FY13 as well, given the impact of offshore wage hikes. We believe that the full-year revenue contribution from the Openwave location business ($6-7mn) and the IBM product takeover ($8-9mn) should together contribute nearly 6% to FY13 growth, lowering the burden on the organic business. PSL is into pureplay offshore product development (OPD), which is highly discretionary in nature and, thus, exposes the company to higher amount of risk as posed to its peers if situation deteriorates further. We revise our revenue and EPS estimates upwards from Rs 12.04bn/Rs 42.2 to Rs 12.04bn/Rs 42.2 respectively taking into account the depreciated Re and higher contribution from IP.


PSL is one of the cheapest midcaps which has operating margins much higher margins than its peers and comparable to some of the large caps. We believe PSL would in due course undergo a re-rating and trade inline with other good growth mid cap stocks like KPIT Cummins, Mindtree etc. However currently we value the company at 9x FY13E earnings, thus arriving at a target price of Rs 460, 9% higher than our earlier target of Rs 422.



On the margin front, GPM expanded by 94 bps. On the negative side it was impacted by three factors, increasing on-site salaries, the additional Visa cost and acquisition of people in U.S. and Malaysia which was offset by currency gains. On S&M front, the increase was mainly due to increase in on-site salaries and participation in couple of marketing events.


On employee related expenses, PSL witnessed 7.7% sequential increase, mainly due to 4.2% pay hike for its onsite delivery team effective April 1, 2012. As part of its acquisition of Network Performance


Management product, PSL added 72 employees in Malaysia and 12 employees in USA.
PSL's project related expenses went up by 67% sequentially. A higher VISA fee coupled with higher VISA applications was the main reason for this increase. PSL's sales and marketing cost increased due to increments given to the sales team in U.S. effective April 1, 2012 and also due to the participation of some of the branding and marketing events in U.S. The administrative cost increased by 6% due to hiring of additional premises in the SEZ.


PSL's investment income for the quarter came in at Rs75 mn, which was offset by hedging losses of Rs 121 mn, thus resulting in a net loss of Rs 47 mn in the other income portfolio.
The effective tax rate for the quarter was 27.9%, higher sequentially which also impacted the PAT in Q1FY13.


PSL's PAT for the quarter came in at Rs 415.7 mn, up 1% sequentially.
As on 30th June, PSL's hedge position stood at Rs 107.75 mn at an average rate of Rs 52.91. The management mentioned that PSL has consistently followed the policy of hedging ~50% of its net open position on 12 months rolling basis.


PSL's cash and investments as on 30th June stood at Rs 3,596 mn while the total CapEx for the quarter came in at Rs 104 mn. As PSL completed the Hinjawadi and Nagpur projects in Q4FY12 the CapEx for Q1FY13 was on a lower side.



>DISHMAN PHARMA & CHEMICALS

Back on track


Dishman Pharma & Chemicals’ (DPCL) results for Q1FY13 exceeded our expectations. The company reported 30%YoY growth in revenues, 650bps improvement in EBIDTA margin and 156%YoY growth in net profit. The company’s EBIDTA margin improved due to the reduction in the material cost and personnel expenses. There was no supply of Eprosartan mesylate (EM) API to Abbott due to inventory rationalisation. We have a Buy rating for the scrip with a revised target price of Rs101 (based on 7x FY14E EPS).  Strong revenue growth: DPCL reported 30%YoY growth in revenues from Rs2.43bn to Rs3.16bn. The CRAMS segment (62% of revenues) grew by 24%YoY from Rs1.59bn to Rs1.97bn. The others segment (38% of revenues) grew by 51%YoY from Rs785mn to Rs1183mn.


Excellent margin improvement: DPCL’s EBIDTA margin improved by 650bpsYoY from 20.3% to 26.8% due to the decline in the material cost and personnel expenses. Material cost declined by 460bps from 31.2% to 26.6% of revenues due to $5mn (Rs275mn) revenues from high margin contract research business at Bavla. Personnel expenses declined by 250bpsYoY from 29.7% to 27.2% due to the re-structuring at Carbogen Amcis (CA).


Hipo facility to expand: The company’s hipo facility for anticancer products at Bavla has commenced production for an innovative product of Merck. DPCL is likely to expand its capacity from two cells to four cells to cater the additional demand. Astellas, Cephalon and Lexicon have shown interest in using this facility.

Carbogen Amcis has turned around: DPCL’s 100% subsidiary Carbogen Amcis (CA) (42% of revenues) achieved 75%YoY growth in revenues from Rs760mn to Rs1330mn. Its EBIDTA margin improved from -3.7% to 16.0%. This has led to sharp improvement in EBIDTA margin of CRAMS segment. Leading player in vitamin D segment: DPCL has achieved 60%YoY growth in vitamin D segment from Rs398mn to Rs637mn. The EBIDTA margin for this business declined by 360bps YoY from 24.6% to 21.0%. The company’s new manufacturing facility at Bavla went on stream in Q4FY12 and is expected to
contribute significantly in FY13.


Valuations: We expect DPCL to benefit from good growth in CRAMS, Vitamin D3 and anticancer products. At the CMP of Rs79, the stock trades at 7.2x FY13E EPS of Rs11.0 and 5.5x FY14E EPS of Rs14.4. We have a Buy rating for the scrip with a revised target price of Rs101 (based on 7x FY14E EPS of Rs14.4) with an upside of 27.6% over CMP (earlier target of Rs72 based on 5x FY14E EPS).

RISH TRADER

>CIPLA: Launch of vancomycin in the US market

PAR EXCELLENCE


Cipla’s results for Q1FY13 were better than our expectations. The company reported 24%YoY growth in revenues, 480bps improvement in EBIDTA margin and 58%YoY growth in net profit. The sales growth predominantly came from domestic operations, which grew by 30%YoY. Cipla’s margin improvement came solely from reduction in material cost. Cipla supplied escitalopram to Teva , which has 180-day exclusivity in the US market. The company’s interest cost declined by 91%YoY from Rs120mn to Rs11mn due to the reduction in debt. We have a Buy rating for the scrip with a revised target price of Rs429 (based on 22x FY14E EPS) from the earlier target price of Rs390 (based on 20x FY14E EPS).

Excellent sales growth: Cipla reported 24%YoY growth in revenues from Rs15.83bn to Rs19.58bn due to excellent growth in the domestic market and benefit of rupee depreciation against the dollar. The sales growth in various geographies is as follows: India formulations 30%, Export- formulations 23%, API -2%. The strong domestic growth was in anti-infective and anti-asthmatic segments. Export of formulation was driven by supply of escitalopram to Teva during its 180-days exclusivity period in the US.
 
Margin improvement: Cipla’s EBIDTA margin improved by 480bpsYoY from 22.8% to 27.6% solely due to the reduction in material cost. Material cost declined by 480bps from 42.2% to 37.4% of revenues due to the change in product mix and lower sales of anti-HIV products. The improvement of margin was also due to the supply of escitalopram to Teva and launch of vancomycin in the US market.

Indore SEZ progressing well: Cipla’s Indore SEZ has witnessed increased capacity utilization of 45-50%. The SEZ unit contributes around Rs1.90bn to revenues per quarter. This is likely to be the future growth driver for the company.  Leading player in antiasthma segment: Cipla is the market leader in antiasthma segment and has over 80%MS in the inhaler segment. Four out of top 5 products of Cipla are in anti-asthmatic segment. The company markets the full range of anti-asthmatic products in the domestic market.
 
Valuations: We expect Cipla to benefit from favorable currency movement and supply of escitalopram to Teva. The company is likely to benefit from excellent growth in anti-infective and anti-asthmatic segments in the domestic market. At the CMP of Rs339, the stock trades at 20.5x FY13E EPS of Rs16.5 and 17.4x FY14E EPS of Rs19.5. We have a Buy rating on the scrip with a revised target price of Rs429 (based on 22x FY14E base EPS of Rs19.5) from our
earlier target of Rs390 (based on 20x FY14E EPS).





RISH TRADER